Hutchmed (China) announced that the latest and updated data from the ESLIM-1 Phase III study of surufatinib, as well as several studies on compounds independently developed by Hutchmed (China), will be presented at the 2024 American Society of Hematology Annual Meeting in San Diego, USA from December 7th to 10th, 2024, and at the 2024 European Society for Medical Oncology Asia Conference in Singapore from December 6th to 8th, 2024. Hunan Xiang Jia Husbandry announced that in October 2024, they sold 4.3398 million live poultry, with sales revenue of 96.3574 million yuan, and an average selling price of 10.97 yuan/kg. The month-on-month changes were 12.15%, 15.12%, -0.59%, while the year-on-year changes were 8.09%, 9.45%, -6.54%.
11月6日午间公告一览：和黄医药索乐匹尼布长期治疗有效提升血小板计数
November 6th noon announcement summary: hutchmed (china) announces that surufatinib long-term treatment effectively increases platelet count.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated